Excessive intake of sorbitol, a type of sugar naturally found in many fruits and used as a sugar substitute, may…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
CHOLESTASIS
NewsNew biomarkers may help detect pregnancy-linked liver complication
Levels of the metabolite palmitic acid and the protein ACSL1 in the bloodstream can accurately detect the presence and severity…
CHOLANGITIS
NewsNew trial testing probiotic for reducing liver inflammation in PSC
Liscure Biosciences has launched a Phase 2 clinical trial to test whether its experimental probiotic LB-P8 can improve gut…
CHOLANGITIS
NewsLivdelzi maintains benefits for up to 3 years in PBC: Phase 3 data
Up to three years of treatment with Gilead Sciences‘ Livdelzi (seladelpar) results in sustained reductions in itching and biomarkers…
BILIARY ATRESIA
NewsBetter to have Kasai surgery before liver transplant for biliary atresia
For infants with biliary atresia, undergoing standard Kasai surgery — a procedure to restore the flow of the digestive…
The most recent assessment of liver stiffness best predicts the future risk of liver disease progression among adults with…
CHOLANGITIS
NewsSeladelpar approved in Canada as Lyvdelzi to treat adults with PBC
Health Canada has conditionally approved Gilead Sciences’ seladelpar — to be marketed in the country under the brand name…
CHOLANGITIS
NewsBlood marker can predict liver function improvement in PBC
A blood marker of inflammation called lymphocyte-to-monocyte ratio (LMR) is an independent predictor of liver recompensation — when liver function…
CHOLANGITIS
NewsLarge study finds risks of liver cancer low for certain PSC patients
Hepatocellular carcinoma (HCC), the most common type of liver cancer, is relatively rare among people with primary sclerosing cholangitis…
A class of medicines called PPAR agonists that modulate genes involved in inflammation and scarring improve biochemical markers of liver…